Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Koziorowska A et al. | 2016 | intact cell/cell culture, pig pinealocytes | magnetic field, 50/60 Hz | 2.5 mT |
Koziorowska A et al. | 2017 | intact cell/cell culture, human neonatal fibroblast BJ | 50/60 Hz, magnetic field, low frequency, signals/pulses | 2.5 mT |
Koziorowska A et al. | 2018 | - | 50/60 Hz, low frequency, magnetic field | - |
Koziorowska A et al. | 2017 | intact cell/cell culture, pig anterior pituitary gland cells | magnetic field, 50/60 Hz, low frequency | 2–6 mT |
Koziorowska A et al. | 2017 | intact cell/cell culture, 143B (human osteosarcoma cell line), BJ (human fibroblast cell line) | 50/60 Hz, magnetic field | 2–6 mT |
Kula B et al. | 1996 | intact cell/cell culture, fibroblasts | magnetic field, static magnetic field, low frequency, 50/60 Hz | 20–490 mT |
Kurian MV et al. | 2012 | intact cell/cell culture, H9c2 cells (myoblast from embryonal rat myocard) | magnetic field, 50/60 Hz, co-exposure | 1–240 µT |
Kwee S et al. | 1995 | intact cell/cell culture, AMA cells (human epithelial amnion cells) and K14 cells (human skin fibroblasts) | magnetic field, low frequency, 50/60 Hz | 25–180 µT |
Lazzarini R et al. | 2023 | intact cell/cell culture, MDA-MB-231 cells (breast cancer cell line) and MDA-MB-231 (human breast cell line) | magnetic field, 50/60 Hz | - |
Lim HM et al. | 2021 | intact cell/cell culture, human dental pulp stem cells | magnetic field, signals/pulses, low frequency, 50/60 Hz | 10 mT |
Loberg LI et al. | 2000 | intact cell/cell culture, MCF-7, ZR-75-1, T-47D, and MDA-MB-231 (breast cancer cell line) and normal human breast epithalial cells | magnetic field, 50/60 Hz | 1 mT |
Luukkonen J et al. | 2014 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz, co-exposure | 100 µT |
Mansoury F et al. | 2021 | intact cell/cell culture | magnetic field, low frequency, 50/60 Hz | 0.25–2 mT |
Mansoury F et al. | 2022 | intact cell/cell culture, human gastric adenocarcinoma (AGS) and human normal fibroblast (Hu02) cell lines | magnetic field, 50/60 Hz | - |
Markkanen A et al. | 2001 | yeast (<i>Saccharomyces cerevisiae</i>/SEy2101a) | magnetic field, 50/60 Hz, co-exposure | 120 µT |
Masoudi-Khoram N et al. | 2022 | intact cell/cell culture, MCF-7 and MDA-MB-231 (human breast cancer cell lines) | magnetic field, low frequency, 50/60 Hz | - |
Master AM et al. | 2016 | - | magnetic field, 50/60 Hz, signals/pulses, co-exposure | - |
Mercado-Sáenz S et al. | 2019 | - | magnetic field, 50/60 Hz, signals/pulses | - |
Miyakoshi J et al. | 1994 | intact cell/cell culture, human leukemia cell lines (HL60RG, CCRF-CEM9), GM0637 cells (normal human fibroblast cell line), TAT2SF cells (human Louis-Bar syndrome fibroblast cell line) | magnetic field, 50/60 Hz, also other exposures without EMF | 400 mT |
Miyakoshi J et al. | 1997 | intact cell/cell culture, MeWo cells (malignant melanoma cells) | magnetic field, 50/60 Hz, also other exposures without EMF | 400–500 mT |
Miyakoshi J et al. | 2000 | intact cell/cell culture, MO54 cells (derived from a human malignant glioma) | magnetic field, 50/60 Hz, co-exposure | 5–400 mT |
Morabito C et al. | 2017 | - | magnetic field, 50/60 Hz | - |
Mousavi Maleki NS et al. | 2022 | intact cell/cell culture, human adenocarcinoma gastric cancer cell line (AGS) | magnetic field, 50/60 Hz | - |
Moya-Gómez A et al. | 2023 | intact cell/cell culture, BV2 cells (immortalized murine microglial cell line), SHSY5Y cells, (immortalized human neuroblastoma cell line), primary mouse microglia and neurons, animal, mongolian gerbils <i>(Meriones unguiculatus)</i> (stroke model) | 50/60 Hz, magnetic field | - |
Nakayama M et al. | 2016 | intact cell/cell culture, macrophages (RAW 246) | magnetic field, 50/60 Hz, co-exposure | 500 µT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.